Reason(s) for Decision: The Pharmaceutical Benefit Advisory Committee met to consider applications for changes to the Prescribed List and made the following recommendations: 1. Items to be added to the Prescribed List1.1 Ticagrelor 60mg tablets (interim recommendation November 2019) 1.2 Sodium hyaluronate 0.2% eye drops preservative free 1.3 VitA-POS™֥ eye ointment preservative free 1.4 Colesevelam 625mg tablets 1.5 Colestipol 5g granules sachets sugar free 1.6 Mesalazine 1g suppositories 1.7 Trimbow™ 87micrograms/dose / 5micrograms/dose / 9micrograms/dose inhaler 1.8 Rivaroxaban 2.5mg tablets, 10mg tablets 1.9 Captopril 25mg/5ml oral solution sugar free 1.10 Aciclovir eye ointment (temporary reinstatement for 6 months only to allow for pharmacy stock to be used up) - Items to be removed from the Prescribed List
Removal from April 2021: 2.1 Pethidine tablets 2.2 Flurazepam capsules Removal from July 2020: 2.3 Pethidine injection 2.4 Aminophylline injection 2.5 Danazol capsules 2.6 Demeclocycline capsules 2.7 Diethylstilbestrol 5mg tablet 2.8 Dihydrocodeine injection 2.9 Disopyramide injection 2.10 Ephedrine injection 2.11 Fentanyl injection 2.12 Pergolide tablets 2.13 Sodium cromoglicate caps 100mg 2.14 Uvistat sun screen Factor 30 2.15 Phenelzine tablets 2.16 Phenindione tablets 2.17 Phenoxybenzamine capsules 2.18 Pimozide tablets - Other changes to the Prescribed List
The following two products were recommended for reimbursement as ‘Generic only’. 3.1 Budesonide 64micrograms/dose nasal spray 3.2 Bimatoprost 300micrograms/ml eye drops The recommendation reflects current evidence and expert advice and ensure that patients in Jersey have access to an appropriate range of modern, safe and effective treatments from their GPs and community prescribers at a proportionate cost to the Fund. |